Search results
Nov 13, 2023 · Paxlovid is an oral antiviral medication used to treat COVID-19. Previous studies demonstrate the medication’s effectiveness in reducing hospitalization and death in cases of severe COVID-19. Since the integration of Paxlovid into COVID-19 treatment, some patients have reported virologic rebound.
Sep 26, 2023 · The theory behind Paxlovid rebound is that the treatment is so effective at suppressing the virus that the immune system does not ramp up its cellular and antibody...
Mar 25, 2024 · There have been reports of a “rebound” of COVID symptoms in some people within 2 to 8 days after completing the five-day course of Paxlovid; in those cases, some have tested positive again but have no symptoms; others have a recurrence of symptoms.
Dec 13, 2022 · Wolfgang Rattay/Reuters. By Dani Blum. Updated. Dec. 13, 2022, 12:57 p.m. ET. Reports of “Paxlovid rebound” popped up in the spring of 2022, as some people who had taken the antiviral...
Center for Infectious Disease Research and PolicyData: Optimal initiation of Paxlovid in hospitalized COVID patients is 3 to 5 days
Taking the SARS-CoV-2 antiviral drug nirmatrelvir-ritonavir (Paxlovid) 3 to 5 days after COVID-19 sy...
12 hours ago
- Medical Xpress
Optimal timing maximizes Paxlovid benefits for treating COVID-19
Researchers have described the optimal timing for COVID-19 patients to take the antiviral, Paxlovid, to get the most benefit from the treatm...
1 day ago
Feb 1, 2024 · Paxlovid rebound is a term used to describe when a person experiences worsening of COVID symptoms after initially getting better after taking Paxlovid (nirmatrelvir / ritonavir). But COVID rebound isn’t a side effect of Paxlovid.
Mar 20, 2024 · One of the main open queries is about the role of the antiviral drug Paxlovid (nirmatrelvir and ritonavir), which aims to prevent mild or moderate COVID-19 from...
Dec 21, 2023 · Early treatment with a first-line therapy (nirmatrelvir/ritonavir [Paxlovid] or remdesivir) or second-line therapy (molnupiravir) prevents hospitalization and death among patients with mild-to-moderate COVID-19 who are at risk for severe disease and is recommended by the National Institutes of Health COVID-19 Treatment Guidelines.
